Malaria: Antibody drug 88% effective in preventing infection
news desk Laugh
A National Institutes of Health clinical study found that a single dose of an antibody drug safely protects healthy, non-pregnant adults from malaria infection during the six-month intense malaria season in Mali, Africa. The antibody was up to 88.2% effective in preventing infection over a 24-week period, demonstrating for the first time that a monoclonal antibody can prevent malaria infection in an endemic area. These results were published today in The New England Journal of Medicine It was presented at the 2022 American Society of Tropical Medicine and Public Health Annual Meeting in Seattle.
Anthony S. said: Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health: “We need to expand the arsenal of available interventions to prevent malaria infection and accelerate efforts to eliminate the disease.” “These study results suggest that monoclonal antibodies can complement other measures to protect travelers and vulnerable groups such as infants, children and pregnant women from seasonal malaria and help eliminate malaria from specific geographic areas.”
NIAID sponsored and funded the trial, which was led by Peter D. Crompton, MD, MPH, and Kassoum Kayentao, MD, MPH, Ph.D. Dr. Crompton is the Head of the Department of Malaria Infection Biology and Immunology at the NIAID Laboratory of Immunogenetics, and Dr. Kaintao is a Professor at the University of Science, Technologies and Technologies (USTTB) in Bamako, Mali.
Read more on National Institutes of Health